title: Toxicity assessment of pramipexole in juvenile rhesus monkeys.
abstract: Pramipexole (PPX) is a dopamine agonist approved for the treatment of the signs and symptoms of idiopathic Parkinson's disease as well as restless leg syndrome. The objective of this study was to investigate the toxicity of PPX when administered orally to juvenile rhesus monkeys once daily for 30 weeks, and to assess the reversibility of toxicity during a 12-week recovery. Rhesus monkeys (N=4 males and 4 females/group; 22-24 months of age) were orally treated daily for 30 weeks with 0.0, 0.1, 0.5 or 2.0 mg/kg PPX, and subjects were assessed daily using the NCTR Operant Test Battery (OTB). Clinical chemistry, hematology, ophthalmology and other standard postmortem toxicological evaluations, including histopathology and neuropathology as well as toxicokinetics were performed. The systemic exposure to PPX was higher than that at therapeutic doses in man and AUC(0-24 h)-data increased proportionally to dose. Blood pressure significantly decreased over time in all groups including control. Near the end of treatment, there were statistically significant decreases in heart rate for the 0.5 and 2.0 mg/kg/day groups compared to control. After 4 weeks of dosing, serum prolactin was significantly decreased in all treatment groups compared to control. This decrease remained at the end of treatment in the 0.5 and 2.0 mg/kg/day groups. In summary, administration of PPX at doses of up to 2.0 mg/kg/day for 30 weeks to juvenile rhesus monkeys produced adverse findings which were attributable to its pharmacological properties, including hypoprolactinemia.
authors: Division of Neurotoxicology, National Center for Toxicological Research, U.S. Food & Drug Administration, 3900 NCTR Rd., Jefferson, AR 72079, USA. tucker.patterson@fda.hhs.gov
authors: Tucker A
authors: TA
authors: Patterson
authors: Mi
authors: M
authors: Li
authors: Charlotte E
authors: CE
authors: Hotchkiss
authors: Annerose
authors: A
authors: Mauz
authors: Malcolm
authors: M
authors: Eddie
authors: Andreas
authors: A
authors: Greischel
authors: Birgit
authors: B
authors: Stierstorfer
authors: Ulrich
authors: U
authors: Deschl
authors: Merle G
authors: MG
authors: Paule
mesh_terms: D000284:Administration, Oral; D000367:Age Factors; D000818:Animals; D052160:Benzothiazoles / Q000008:administration & dosage / Q000097:blood / Q000633:toxicity* / Q000652:urine; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D008253:Macaca mulatta; D008297:Male; D000077487:Pramipexole; D011388:Prolactin / Q000097:blood; D036401:Toxicity Tests, Chronic / Q000379:methods*
chemical_list: D052160:Benzothiazoles; D000077487:Pramipexole; D011388:Prolactin